/ /

  • linkedin
  • Increase Font
  • Sharebar

    New EDOF IOL features novel optical design, reduced side effects, advanced chromatic optics

     

    Real-world outcomes

    Dr. Kretz and colleagues also conducted a prospective study to evaluate functional results and patient satisfaction after implantation of the AT LARA. They analyzed results from 17 eyes of 10 patients (median preoperative SE 0.875 D) that were targeted for emmetropia.

    The study found the refractive outcomes to be excellent. Achieved SE was within 0.75 D of target in all eyes, ±0.5 D in 88%, ±0.25 D in 82%, and ±0.125 D in 53%.

    Distance visual acuity results were consistent with the refractive outcomes. Mean monocular logMAR uncorrected and corrected distance visual acuity were both 0, and in binocular testing, mean logMAR uncorrected distance visual acuity was -0.10.

    Binocular mean logMAR distance-corrected intermediate visual acuity measured at 90, 80, and 60 cm was -0.05, 0.10, and 0.03, respectively. In binocular testing at a reading distance of 40 cm, mean logMAR near visual acuity was 0.30 with distance correction and 0.49 uncorrected.

    Compared to previous studies with EDOF IOLs, the AT LARA showed the highest values for visual acuity in the intermediate range, said Dr. Kretz, who is also consultant and research coordinator, International Vision Correction Research Centre Network, University of Heidelberg, Heidelberg, Germany.

    “These visual acuity results for distance and intermediate are exceptional, and in correspondence with them, the monocular and binocular defocus curves showed no dip in the intermediate range,” Dr. Kretz reported. “For near, patients still achieve good functional vision, and overall we found high satisfaction with near vision.”

    Patient satisfaction for the lens was evaluated using the McAlinden quality of vision questionnaire. The results showed that 71% of patients agreed that the surgery offered them spectacle independence for near, and all patients answered that the surgery provided them spectacle independence for intermediate and distance.

    About 40% of patients reported never needing glasses for near, and the others were evenly divided between needing reading glasses most of the time or seldom. Eighty-six percent of patients reported never wearing glasses for intermediate or distance, and the remaining minority seldom wore glasses for those distances.

    “All of the patients said they would choose the lens again,” Dr. Kretz said.

    In testing with a simulated night vision scene, almost 75% of patients reported experiencing glare, but it was rated as being no more than occasionally. Halo affected 29% of patients occasionally and 14% quite often, while 29% of patients reported occasional starburst. However, no patient rated their halo as worse than minimal and bother ratings for all three symptoms were consistently no worse than minimal.

    Florian T. Kretz, MD

    e. [email protected]

    e. [email protected]

    Steven C. Schallhorn, MD

    e. [email protected]

    Dr. Kretz receives travel expenses, research support, and consulting and honorarium fees from Carl Zeiss Meditec and from other companies that market IOLs. Dr. Schallhorn is an employee of Carl Zeiss Meditec.

     

    New Call-to-action

    Poll

    View Results